April 11, 2025

Physical training has a positive effect on the sexual health of women with metastatic breast cancer

Physical training has a positive effect on the sexual health of women with metastatic breast cancer

Metastatic breast cancer requires complex and lengthy treatment, the side effects of which affect the quality of life of patients. These often include sexual problems. In a large international randomized exercise intervention trial, researchers at the German Cancer Research Center (DKFZ) and the NCT Heidelberg have now shown that women who received a nine-month supervised exercise program reported significantly fewer symptoms than women who did not participate in the training program.

The treatment of metastatic breast cancer is associated with a variety of adverse effects. However, in contrast to clinical side effects (e.g. neutropenia, nausea or vomiting), for which there are established treatment recommendations, sexual and vaginal problems are often still a taboo subject that is rarely discussed and little research is done on it.

In the international, randomized controlled PREFERABLE-EFFECT study, 355 women with metastatic breast cancer were repeatedly asked about their symptoms and problems over a period of nine months. Half of the participants completed a nine-month guided exercise program consisting of strength, endurance, and balance exercises twice a week for one hour each. The control group received only general exercise recommendations. The recently published primary analyses had shown significant improvements in fatigue and quality of life as a result of the training (Hiensch et al. Nature Medicine 2024). A current analysis of the study data at the DKFZ now focused on the information on sexual and vaginal problems as well as on other less considered symptoms.

The results show that many study participants suffered from low sexual activity, little interest in sex, limited sexual satisfaction, vaginal dryness or pain during intercourse at the beginning of the study. The guided training program led to an improvement.

After six months, the participants in the training group had higher scores for sexual activity/interest when rated on a scale from 0 to 100, with an average increase of six points compared to the control group. This difference was statistically significant and can be categorized as a small to moderate effect, which still existed after nine months. In addition, the proportion of women in the training group who found sex pleasurable increased. Vaginal problems also improved to a statistically significant extent after six months, with the training effect being most pronounced in women under 50 years of age. In addition, the training program significantly alleviated other chemotherapy side effects in patients undergoing chemotherapy, such as mouth sores and irritated eyes.

“The study underlines the importance of exercise as a supportive measure to improve the quality of life of women with metastatic breast cancer,” says senior author Karen Steindorf, head of a department at the DKFZ and the NCT Heidelberg. Further analyses are currently being carried out in the PREFERABLE project, including on blood samples from the participants, in order to better understand the mechanisms of action and possible modifying factors. The aim is to adapt the training programs even more individually for each patient in the future and to further increase their effectiveness.


M.E. Schmidt, A.E. Hiensch, J. Depenbusch, E.M. Monninkhof, J. Belloso, D. Clauss, N. Gunasekara, M. Trevaskis, H. Rundqvist, J. Wiskemann, J. Müller, M.G. Sweegers, A. Schneeweiss, R. Altena, J. Kufel-Grabwska, R.M. Bijlsma, L. van Leeuwen-Snoeks, D. ten Bokkel Huinink, G. Sonke, S. Brandner, P. Savas, Y. Antill, M. White, N. Ancizar, E. van der Wall, N.K. Aaronson, E. Senkus, A. Urruticoechea, E.M. Zopf, W. Bloch, M.M. Stuiver, Y. Wengstrom, A.M. May, K. Steindorf: Impact of Exercise on Sexual Health, Body Image, and Therapy-related Symptoms in Women with Metastatic Breast Cancer: The Randomized Controlled PREFERABLE-EFFECT Trial
International Journal of Cancer 2025, DOI: https://doi.org/10.1002/ijc.35429

Our latest News

discover more
BioMed X and Boehringer Ingelheim Expand XSeed Labs to Advance Next-Generation Eye Therapies

BioMed X and Boehringer Ingelheim Expand XSeed Labs to Advance Next-Generation Eye Therapies

Ridgefield, CT, USA, July 9, 2026 – BioMed X, a leading innovation engine for pharma, and Boehringer Ingelheim today announced the launch of a new research team at XSeed Labs, the established innovation incubator embedded within Boehringer’s U.S. R&D headquarters in Ridgefield, Connecticut. The newly established research team, Team NIB (New Platform for Next-Generation Intraocular […]

Clinical Trial on Mild Stroke: Inpatient or Outpatient Treatment?

Clinical Trial on Mild Stroke: Inpatient or Outpatient Treatment?

Researchers at Heidelberg University’s Faculty of Medicine are investigating a new care model for older adults with mild strokes at the Heidelberg University Hospital’s Department of Neurology. The Joint Federal Committee (G-BA) is funding the ARTIFICE study with approximately 2.4 million euros. Full Text in German below. Klinische Studie zu leichtem Schlaganfall: stationär oder ambulant […]

VERAXA Biotech to Launch AI-enabled Drug Discovery Collaboration with Ardigen to Support Growing BiTAC® Pipeline

VERAXA Biotech to Launch AI-enabled Drug Discovery Collaboration with Ardigen to Support Growing BiTAC® Pipeline

Ardigen platform supports VERAXA’s in-house AI capabilities to optimize cancer target pair selection for conditionally active t cell engagers (TCEs) and antibody drug conjugates (ADCs) ZURICH, SWITZERLAND – July 13, 2026 — VERAXA Biotech AG (NASDAQ: VRXA; “VERAXA”), an emerging leader in designing novel cancer therapies, today announced a collaboration with Ardigen S.A., an AI-driven computational partner for modern […]

GET IN TOUCH

Stay Updated with bioRN’s Newsletter

Sign up for our newsletter to discover more!
* required

BioRN (BioRN Network e.V. and BioRN Cluster Management GmbH) will use the information you provide on this form to be in touch with you and to provide updates and marketing. Please let us know all the ways you would like to hear from us:

You can update your subscription preferences or unsubscribe at any time. Just follow the unsubscribe or update link in the footer of automated emails you receive from us, or by contacting us at info@biorn.org. We will treat your information with respect. For more information about our privacy practices please visit our website: www.biorn.org. By clicking below, you agree that we may process your information in accordance with these terms.

We use Mailchimp as our marketing platform. By clicking below to subscribe, you acknowledge that your information will be transferred to Mailchimp for processing. Learn more about Mailchimp's privacy practices.

Intuit Mailchimp